Mr. Chair, AECL funding for its nuclear laboratories in the 2013-14 main estimates has remained constant at $102 million. As has been the case in recent years, and in the context of the ongoing restructuring, AECL has required additional funding to meet its ongoing operational requirements.
This year, budget 2013 provided AECL with $141 million, over two years, on an accrual basis. This funding will enable AECL to ensure the production of medical isotopes, health and safety upgrades and environmental protection.
Additionally, AECL continues to receive statutory funding for addressing legal obligations relating to the divestiture of its former CANDU reactor division. These requirements are decreasing, and $109 million was provided for AECL in—